S-1/A: Oragenics Seeks Up to $5 Million in Public Offering to Advance Concussion Treatment

Oragenics, Inc. is conducting a public offering of up to 15,151,515 units to fund the development of its ONP-002 concussion treatment and for general corporate purposes.

Summary

• Oragenics, Inc. is offering up to 15,151,515 units, each consisting of one share of common stock (or a pre-funded warrant) and one common warrant, at an assumed price of $0.33 per unit.
• The company aims to raise approximately $4.3 million in net proceeds from this offering.
• The primary use of funds will be to advance the clinical trials of ONP-002, a drug candidate for treating mild traumatic brain injury (concussion).
• The offering also includes pre-funded warrants for investors who would exceed a 4.99% (or 9.99%) ownership threshold, exercisable at $0.001 per share.
• Common warrants are exercisable at $0.33 per share and expire five years from issuance.
• The offering is a 'reasonable best efforts' offering, meaning there is no minimum amount of securities that must be sold.
• The offering is expected to terminate no later than January 31, 2025.
• The company's common stock is listed on the NYSE American under the symbol OGEN.

Sentiment

Score: 4

Explanation: The document presents a mix of positive and negative aspects. While the company has a promising drug candidate and a novel delivery method, it faces significant financial challenges and risks. The need for a capital raise and the going concern warning from the auditor temper the positive aspects.

Positives

• The offering will provide funding for the clinical development of ONP-002, a promising drug candidate for concussion treatment.
• The company has completed Phase 1 clinical trials for ONP-002, showing it is safe and well-tolerated.
• The company has a novel breath-powered intranasal delivery device for ONP-002, which may offer advantages over standard delivery systems.
• The company has secured intellectual property protection for the ONP-002 compound and the delivery device.
• The company has engaged experienced medical advisors to oversee the clinical trials.

Negatives

• The company has incurred significant losses since its inception and has limited financial resources.
• The company may not be able to secure additional funding if this offering is not successful.
• The company's auditor has expressed substantial doubt about its ability to continue as a going concern.
• The company may not be able to satisfy the continued listing standards of the NYSE American.
• The company has limited neurology-specific experience and may need to invest significant resources to establish these capabilities.
• The company's product candidates have not been approved for sale and may not be successful.
• The company faces significant competition from other companies with greater resources and experience.
• The market opportunities for the company's neurology product candidates may be smaller than anticipated.
• The company's stock price has been volatile and may fluctuate significantly.

Risks

• The company has a history of losses and may not be able to achieve profitability.
• The company's ability to continue as a going concern is uncertain.
• The company may be delisted from the NYSE American if it does not meet continued listing standards.
• The company's product candidates may not be approved for sale or may not be commercially successful.
• The company faces significant competition in the pharmaceutical industry.
• The company's intellectual property may not be adequately protected.
• The company may be subject to litigation or regulatory action.
• The company's stock price may be volatile and may decline significantly.
• The company may experience delays in clinical trials or regulatory approvals.
• The company may not be able to raise sufficient capital to fund its operations.

Future Outlook

The company intends to use the net proceeds from this offering to fund its ongoing ONP-2 concussion clinical trials, along with other related research and development activities, as well as for working capital and other general corporate purposes. The company will need to raise additional capital to complete the development and commercialization of its ONP-002 product candidate.

Management Comments

• The company expects to focus its resources on the continued development of the Neurology Assets and primarily ONP-002.
• The acquisition is expected to build on our expertise in intranasal platforms and expand our portfolio into more areas of unmet medical needs.
• The company believes the proprietary nasal formulation and intranasal administration allows for rapid and direct accessibility to the brain.
• The company believes that its recent work has increased the final dose levels significantly while also providing for improved intranasal drug delivery and adhesion and, thus, longer absorption times.

Industry Context

The global market for concussion treatment was valued at $6.9 billion in 2020 and is forecast to reach $8.9 billion by 2027, indicating a significant market opportunity for Oragenics' ONP-002 product candidate. The company's focus on intranasal delivery aligns with a trend towards non-invasive and targeted drug delivery methods.

Comparison to Industry Standards

• The company's ONP-002 drug candidate is a neurosteroid, a class of compounds that has shown promise in treating brain injuries.
• The company's intranasal delivery method is similar to other companies exploring non-invasive drug delivery for neurological conditions.
• The company's Phase 1 clinical trial results are comparable to other early-stage clinical trials for similar drug candidates.
• The company's pre-clinical animal studies have shown positive results, which is consistent with industry standards for drug development.
• The company's engagement of experienced medical advisors is a common practice in the pharmaceutical industry.

Stakeholder Impact

• Shareholders will experience dilution as a result of the offering.
• Employees may be affected by the company's financial challenges.
• Customers (potential patients) may benefit from the development of ONP-002.
• Suppliers and creditors may be affected by the company's financial situation.

Next Steps

• The company plans to use the proceeds from the offering to fund its ongoing ONP-2 concussion clinical trials.
• The company anticipates preparing for Phase 2 clinical trials to further evaluate the ONP-002 drugs safety and efficacy.
• The company plans to apply for an Investigational New Drug application with the FDA and conduct a Phase 2 trial in the United States.
• The company anticipates a Phase 2a feasibility study will be performed in Australia with a target initiation date in the third quarter of 2024 to be followed closely by a Phase 2b proof of concept study in the US.

Key Dates

Keywords

Oragenics, ONP-002, concussion, mild traumatic brain injury, public offering, common stock, warrants, pre-funded warrants, clinical trials, neurology, intranasal delivery, pharmaceuticals, biotechnology